Bank of the Sierra reports record earnings
Sierra Bancorp reported record earnings boosted by lower loan and lease losses and improvements to the overall economy, the bank announced July 19. The parent company of Bank of the Sierra said it had $11.7 million in net income for the quarter ended June 30, or 76 cents per diluted share, compared to $8.3 million Read More →
Teledyne secures Navy contract worth up to $39M
Thousand Oaks-based Teledyne Technologies announced July 19 that its subsidiary, Teledyne Brown Engineering, was awarded a U.S. Navy contract for underwater drones worth as much as $39.2 million. The contract has a maximum base value of $27.4 million over five years, with five one-year option periods and a maximum value of $39.2 million if all Read More →
Losses mount at Resonant, but CEO predicts big things as 5G future approaches
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
FDA accuses Amgen of misleading advertising
The U.S. Food and Drug Administration tagged Amgen with a letter July 7 that says the Thousand Oaks biotech firm made “misleading claims” in advertisements for its drug Neulasta, by suggesting it is more effective than biosimilar competitors. Neulasta is a prescription medication used to reduce infection risk from febrile neutropenia (a low level of Read More →
Income up at Community Bank of Santa Maria
Community Bank of Santa Maria saw its net income rise more than 35% for the most recent quarter as total assets, deposits and net loans all increased. In a July 13 earnings statement, the bank reported net income of $1.44 million for the quarter ended June 30, 36.1% higher than the same quarter of the Read More →
FDA gives Amgen priority review for asthma treatment
Thousand Oaks-based Amgen received a priority review for tezepelumab, a treatment for asthma, from the U.S. Food and Drug Administration, the biotech giant announced July 7. According to Amgen, tezepelumab is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of clients in phase 2 and 3 trials. Read More →
Opinion: Poor communication has many financial clients playing darts in the dark
By John Grace Does this sound familiar to you? • 71% of people are worried about the rising costs of healthcare. • 67% worry about rising costs of living. • 66% are afraid market downturns will affect their savings. • Only 1/3 have broached the subject with their advisor. These are the findings of The Read More →
